Hepatic metastasis is a major factor in limiting the prognosis of patients with colon carcinoma. Recent investigations indicate a correlation between plasminogen activator profiles and hepatic metastasis. We examined the effectiveness of tissue plasminogen activator (tPA) gene therapy using a hepatic metastasis model of murine colon carcinoma. Murine colon carcinoma Colon 26 cells transduced with an MFGtPA retroviral vector (Colon 26/tPA) or an MFGLacZ retroviral vector (Colon 26/LacZ) were injected into the liver via the superior mesenteric vein of BALB/c mice, whose survival rates were checked daily. The mean survival rate of mice with hepatic metastasis induced by Colon 26/LacZ was 23.1 days, whereas that of mice with Colon 26/tPA was Ͼ100 days. The in vitro proliferation of Colon 26/tPA was comparable with that of Colon 26/LacZ, and antitumor immunity to wild-type Colon 26 cells was not induced after an intrahepatic injection of Colon 26/tPA. We suggest that transduction of the tPA gene to murine colon cancer is useful against the establishment of hepatic metastasis.
T issue-type plasminogen activator (tPA) is a major activator of the extrinsic fibrolytic system, which plays an important role in thrombolysis. 1 Remarkable changes in plasminogen activator profiles in several types of cancer, such as colon and breast carcinomas, have been reported. [2] [3] [4] These studies indicate that colorectal carcinomas have an increase both in the urokinase-type plasminogen activator (uPA) antigen (Ag) level and in uPA activity compared with normal mucosa, whereas both the tPA Ag level and tPA activity are decreased in colorectal carcinomas compared with normal mucosa. Furthermore, recent studies have demonstrated that the decreased tPA Ag level and tPA activity correlate well with both the recurrence and hepatic metastasis of colorectal carcinomas. 5, 6 The effective treatment of hepatic metastasis is extremely important for the prognosis of patients with advanced colorectal carcinomas who have undergone the surgical resection of the primary tumor. Localized hepatic metastasis from colorectal carcinoma can be treated by surgical resection, although multiple hepatic metastases cannot be removed by surgical treatment. 7 In the present study, we demonstrate that transduction of the tPA gene to murine colon cancer using a retroviral vector was an effective inhibitor of hepatic metastasis.
MATERIALS AND METHODS

Cell lines and animals
Murine colon carcinoma cell line Colon 26 cells were used in the experiment. Female BALB/c mice (8 weeks old; Clea, Tokyo, Japan) were purchased for the induction of hepatic metastasis using the Colon 26 cells. 8 
Retroviral vector and virus-producing cells
Retroviral vectors (MFGtPA and MFGLacZ) were constructed by ligating tPA and LacZ cDNA to an MFG retroviral vector. These cDNAs were inserted between the NcoI and BamHI sites in such a way that the initiation codons of the inserted sequence were placed precisely at the position of the viral envelope initiation codon. 9 CRIP producer cell lines for MFGtPA and MFGLacZ were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine sera. Colon 26 cells were exposed to MFGtPA and MFGLacZ in the presence of polybrene (5 mg/mL, Sigma, St. Louis, Mo) three times every other day and cultured to confluence.
Expressions of tPA and LacZ Ags
Culture media from the Colon 26 cells transduced with MFGtPA (Colon 26/tPA) were collected 24 hours after the media were changed and were analyzed for the tPA Ag using an enzyme-linked immunosorbent assay kit (Biopool AB, Umea, Sweden). Briefly, goat anti-tPA was used as the primary antibody, an anti-tPA horseradish peroxidase conjugate was used as the second antibody, and 3,3Ј,5,5Ј-tetramethylbenzidine was used as the substrate. The absolute quantities of tPA Ag in the samples were calculated from an eight-point standard curve of tPA. 10 Hourly tPA secretion was expressed as ng/mL/10 6 cells/hour. After Colon 26 cells transduced with MFGLacZ (Colon 26/LacZ) had been washed twice with phosphate-buffered saline, they were fixed with 1.25% glutaraldehyde for 15 minutes. After washing four times with phosphate-buffered saline, these cells were stained with 5-bromo-4-chloro-3-indolyl ␤-D-galactoside (X-Gal) solution containing X-Gal (400 mg/mL), 5 mM potassium ferriferrocyanide, and 1 mM MgCl 2 for 24 hours at 37°C.
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In vitro proliferation assay of Colon 26/tPA and Colon 26/LacZ A total of 1 ϫ 10 4 Colon 26/tPA cells (n ϭ 5) and Colon 26/LacZ cells (n ϭ 5) were seeded on a 96-well, flat-bottom plate. At 1, 2, 3, 4, 5, and 6 days after plating, cell viability was analyzed using a colorimetric assay with tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. 12 The percentage of proliferation was calculated using the following formula: 100 ϫ (absorbance on days 2, 3, 4, or 5/absorbance on day 1).
Hepatic implantation of Colon 26/tPA and Colon 26/LacZ
The experiment with hepatic metastasis was performed in the following four groups: 
Antitumor immunity after hepatic implantation of Colon 26/tPA
To confirm that antitumor immunity was induced by the injection of Colon 26/tPA cells into the liver, mice received a peritoneal implantation (2 ϫ 10 6 cells) of wild-type (wt) Colon 26 cells on days 0 (n ϭ 10), 50 (n ϭ 5), and 100 (n ϭ 5) after the hepatic implantation of Colon 26/tPA. 13 The survival of the mice was recorded, and an autopsy was performed after death.
Statistics
Significance was analyzed using the Mann-Whitney U test, and data were expressed as the mean Ϯ SD. To determine differences in survival between groups, Kaplan-Meier nonparametric statistics were used to calculate the actuarial survival rates.
RESULTS
Secretion of tPA Ag and expression of LacZ Ag
The secretion of tPA Ag from both wt Colon 26 and Colon 26/LacZ cells was Ͻ0.5 ng/mL/10 6 cells/hour, whereas that from Colon 26/tPA cells was 10 -12 ng/mL/ 10 6 cells/hour. Of the Colon 26/LacZ cells, 40 -45% were stained using X-Gal staining solution, whereas none of wt Colon 26 and Colon 26/tPA cells were identified; this finding suggests a high transduction efficiency of MFGtPA to Colon 26/tPA.
Hepatic metastasis using Colon 26/tPA and/or Colon 26/LacZ The mean survival rate after hepatic metastasis using Colon 26/tPA cells was Ͼ100 days, whereas that using Colon 26/LacZ was 23.1 days. The mean survival rate after hepatic metastasis of the 1:1 mixture with Colon 26/tPA and Colon 26/LacZ cells was 30.4 days, whereas that of the 1:3 mixture with Colon 26/tPA and Colon 26/LacZ cells was 27.9 days. In the mice using Colon 26/LacZ, multiple hepatic metastasis were observed, whereas in those using Colon 26/tPA, there was no hepatic metastasis. Lung and pleural metastases were observed in mice surviving for Ͼ30 days after hepatic metastasis of the 1:1 mixture and 1:3 mixture with Colon 26/tPA and Colon 26/LacZ cells. The actuarial survival curve is shown in Figure 1 
In vitro proliferation activity
The percentage of proliferation of Colon 26/LacZ was 100, 178 Ϯ 8, 406 Ϯ 38, 700 Ϯ 57, 925 Ϯ 41, and 1082 Ϯ 58 on days 1, 2, 3, 4, 5, and 6, respectively, whereas that of Colon 26/tPA was 100, 196 Ϯ 17, 446 Ϯ 45, 720 Ϯ 49, 920 Ϯ 56, and 1065 Ϯ 44 on days 1, 2, 3, 4, 5, and 6 (Fig  3) , respectively. There was no statistical difference between the groups.
Antitumor immunity after hepatic implantation of Colon 26/tPA If Colon 26/tPA were rejected after hepatic implantation via the superior mesenteric vein, antitumor immunity to Colon 26/tPA and wt Colon 26 cells would be induced in the surviving mice. To confirm the possibility of the induction of antitumor immunity, the surviving mice were rechallenged with wt Colon 26 cells at 0, 50, and 100 days after hepatic implantation of Colon 26/tPA. The mean survival rates in mice with peritoneal metastasis on days 0, 50, and 100 after the hepatic implantation of Colon 26/tPA were 17.0, 15.0, and 14.2 days, respectively. As shown in Figure 4 , there was no significant difference between the groups.
DISCUSSION
This study clearly indicated that transduction of the tPA gene to murine colon cancer cell line Colon 26 cells renders the cells insusceptible to the formation of both hepatic metastasis and peritoneal metastasis using hepatic metastatic and peritoneal metastatic animal models. Significantly, the formation of hepatic metastasis was completely inhibited by transduction of the tPA gene to the cancer cells. It has been reported that human colorectal carcinogenesis is associated with an increase in both uPA and plasminogen activator inhibitor type 1 and type 2 that is accompanied by a decreased level of tPA, which contributes to the invasive growth and hepatic metastasis. 2, 3 In addition, recent investigations have demonstrated remarkable changes in plasminogen activator profiles in breast cancers and brain tumors. 4, 14 These findings suggest that transduction of the tPA gene to cancer cells is followed by a decrease in carcinogenesis and a reduced metastatic potential in murine colon cancer.
Transduction of the tPA gene to murine colon cancer Colon 26 cells did not result in growth inhibition of these cells in vitro or in antitumor immunity to these cells. These findings suggest that the cancer cells implanted in the liver after transduction of the tPA gene have no potential to proliferate and invade the extracellular matrix. However, the effect of in vivo transduction with the tPA gene on cancer growth after the implantation of cancer cells remains to be determined.
The cancer cells must adhere to the endothelium of the metastatic organs so as to penetrate into the host tissue and establish metastases. 15, 16 It has been reported that several cell surface adhesion molecules, including integrins, lectins, and members of the immunoglobulin superfamily are involved in mediating tumor cell interactions within the endothelium. 17 In addition, recent investigations have demonstrated that coagulation factors such as thrombin and thrombospondin increase the metastatic potential of tumor cells. 18, 19 Cancer cells transduced with tPA gene possess an increased proteolytic activity, which might inhibit their attachment to the endothelium through an inhibition of the embolic formation within cancer cells. The observation that transduction of the tPA gene to murine colon cancer cells was more effective for the inhibition of hepatic metastasis than for the inhibition of peritoneal metastasis suggests that tPA plays a critical role in hepatic metastases of murine colon cancer through this mechanism. However, detailed analysis will be required regarding whether tPA gene-transduced cells actually have an altered ability to invade extracellular matrix.
The finding that transduction of the tPA gene to colorectal carcinomas inhibits hepatic metastases suggests that hepatic metastasis after colorectal surgery might be decreased with the use of this strategy. Considering that the MFG retroviral vector with the tPA gene had a high transduction efficiency that was proportional to the effective secretion of the tPA Ag, in vivo gene therapy using the tPA gene in colorectal cancers by direct injection of the vectors via a colorectal flexible fiber will be a feasible strategy for metastasis inhibition after colorectal surgery. Further in vitro and in vivo investigations are required to determine the effect of tPA gene therapy on the inhibition of hepatic metastasis in colorectal cancers. 
